Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock.
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med [Yahoo! Finance]